AUPH Stock: Price, Earnings History and SEC Filings
Aurinia Pharmaceuticals Inc. (AUPH) last traded at $16.65, down 3.25% on the latest session and up 2.8% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.28 against an analyst estimate of $0.18, a beat of 55.6%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
AUPH earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $0.28 | $0.18 | +55.56% |
| Mar 2026 | May 7, 2026 | $0.25 | $0.18 | +38.89% |
| Dec 2025 | Feb 26, 2026 | $0.26 | $0.21 | +23.81% |
| Sep 2025 | Nov 4, 2025 | $0.23 | $0.16 | +43.75% |
AUPH beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How AUPH reacts to earnings
Across its last 8 earnings releases, AUPH moved 4.6% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-30 | Before open | -3.25% |
| 2026-08-06 | Before open | +6.19% |
| 2026-05-07 | Before open | -6.80% |
| 2026-02-26 | Before open | -3.19% |
| 2025-11-04 | Before open | +8.35% |
| 2025-07-31 | Before open | +2.15% |
| 2025-05-12 | Before open | +1.50% |
| 2025-02-27 | Before open | -5.03% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
AUPH financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $283M | $287M | – | 101.5% | $2.07 |
| 2024 | $235M | $6M | – | 2.4% | $0.04 |
| 2023 | $176M | -$78M | – | -44.5% | $-0.54 |
| 2022 | $134M | -$108M | – | -80.7% | $-0.76 |
| 2021 | $46M | -$181M | – | -396.8% | $-1.40 |
| 2020 | $50M | -$103M | – | -204.9% | $-0.87 |
| 2019 | $318000 | -$88M | – | -27794.0% | $-0.95 |
| 2018 | $463000 | -$53M | – | -11464.1% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for AUPH
- 10-Q · Oct 30, 2026
- 8-K · Oct 30, 2026Results of operations, Financial statements and exhibits
- 8-K · Aug 19, 2026Other events
- 10-Q · Aug 6, 2026
- 8-K · Aug 6, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 4, 2026Shareholder vote, Financial statements and exhibits
- 8-K · May 11, 2026Acquisition or disposal completed, Financial statements and exhibits
- 10-Q · May 7, 2026
- 8-K · May 7, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 21, 2026
Insider filing activity
AUPH insiders filed 2 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
AUPH news
- Aurinia Revenue Rises on Strong LUPKYNIS Sales and Partner IncomeOct 31, 2026 · theglobeandmail.com
- Aurinia lifts 2026 guidance as LUPKYNIS growth, cash flow and pipeline momentum buildOct 31, 2026 · theglobeandmail.com
- Aurinia Pharmaceuticals (AUPH) Tops Q3 Earnings EstimatesOct 30, 2026 · finance.yahoo.com
- Aurinia: Q3 Earnings SnapshotOct 30, 2026 · finance.yahoo.com
- Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business ProgressOct 30, 2026 · finance.yahoo.com
- Earnings Preview: Ionis Pharmaceuticals (IONS) Q3 Earnings Expected to DeclineOct 28, 2026 · finance.yahoo.com
- Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to DeclineOct 27, 2026 · finance.yahoo.com
- Why Aurinia Pharmaceuticals (AUPH) is a top growth stock for the long termOct 26, 2026 · msn.com
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc. (AUPH) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. Its fiscal year ends in December.